Amid COVID-19 pandemic, Gilead cuts production time for experimental drug in half

The Foster City company hopes to produce 1 million course treatments for COVID-19 patients by the end of the year.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.